Jacobs Levy Equity Management’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-169,048
| Closed | -$2.02M | – | 967 |
|
|
2025
Q3 | $2.02M | Sell |
169,048
-23,022
| -12% | -$184K | 0.01% | 592 |
|
|
2025
Q2 | $1.45M | Sell |
192,070
-74,698
| -28% | -$449K | 0.01% | 684 |
|
|
2025
Q1 | $1.47M | Sell |
266,768
-23,243
| -8% | -$144K | 0.01% | 726 |
|
|
2024
Q4 | $1.67M | Buy |
290,011
+98,285
| +51% | +$942K | 0.01% | 632 |
|
|
2024
Q3 | $1.99M | Sell |
191,726
-2,841
| -1% | -$37.1K | 0.01% | 605 |
|
|
2024
Q2 | $2.52M | Sell |
194,567
-163
| -0.1% | -$2.2K | 0.01% | 563 |
|
|
2024
Q1 | $3.4M | Sell |
194,730
-366,291
| -65% | -$4.85M | 0.02% | 498 |
|
|
2023
Q4 | $5.28M | Buy |
561,021
+215,370
| +62% | +$2.01M | 0.03% | 418 |
|
|
2023
Q3 | $3.86M | Sell |
345,651
-1,697
| -0.5% | -$27.3K | 0.02% | 427 |
|
|
2023
Q2 | $7.43M | Buy |
347,348
+893
| +0.3% | +$26.3K | 0.04% | 322 |
|
|
2023
Q1 | $14M | Sell |
346,455
-2,603
| -0.7% | -$124K | 0.09% | 238 |
|
|
2022
Q4 | $16.2M | Sell |
349,058
-3,245
| -0.9% | -$148K | 0.11% | 215 |
|
|
2022
Q3 | $18.3M | Buy |
352,303
+54,771
| +18% | +$3.2M | 0.14% | 180 |
|
|
2022
Q2 | $14.1M | Buy |
297,532
+19,109
| +7% | +$1.04M | 0.11% | 222 |
|
|
2022
Q1 | $19.8M | Buy |
278,423
+8,293
| +3% | +$540K | 0.13% | 182 |
|
|
2021
Q4 | $20.2M | Buy |
270,130
+16,316
| +6% | +$1.28M | 0.14% | 182 |
|
|
2021
Q3 | $14.4M | Sell |
253,814
-5,739
| -2% | -$284K | 0.1% | 236 |
|
|
2021
Q2 | $11.4M | Buy |
259,553
+17,296
| +7% | +$847K | 0.08% | 268 |
|
|
2021
Q1 | $11.9M | Sell |
242,257
-6,063
| -2% | -$302K | 0.09% | 255 |
|
|
2020
Q4 | $10.5M | Sell |
248,320
-7,744
| -3% | -$341K | 0.09% | 252 |
|
|
2020
Q3 | $11.7M | Sell |
256,064
-8,197
| -3% | -$397K | 0.12% | 189 |
|
|
2020
Q2 | $13.3M | Buy |
264,261
+93,476
| +55% | +$4.84M | 0.14% | 173 |
|
|
2020
Q1 | $8.78M | Buy |
170,785
+84,998
| +99% | +$4.53M | 0.11% | 199 |
|
|
2019
Q4 | $5.3M | Buy |
85,787
+14,413
| +20% | +$894K | 0.05% | 358 |
|
|
2019
Q3 | $4.29M | Buy |
71,374
+13,370
| +23% | +$993K | 0.05% | 360 |
|
|
2019
Q2 | $4.89M | Buy |
+58,004
| New | +$5.22M | 0.07% | 349 |
|
|
2018
Q4 | – | Sell |
-26,822
| Closed | -$2.29M | – | 1003 |
|
|
2018
Q3 | $2.29M | Buy |
26,822
+14,145
| +112% | +$1.42M | 0.03% | 486 |
|
|
2018
Q2 | $1.47M | Sell |
12,677
-16,043
| -56% | -$1.6M | 0.02% | 574 |
|
|
2018
Q1 | $2.32M | Sell |
28,720
-680
| -2% | -$52.3K | 0.04% | 442 |
|
|
2017
Q4 | $1.73M | Buy |
+29,400
| New | +$1.47M | 0.03% | 492 |
|
|
2016
Q2 | – | Sell |
-13,992
| Closed | -$411K | – | 1170 |
|
|
2016
Q1 | $411K | Buy |
+13,992
| New | +$390K | 0.01% | 779 |
|
Other funds holding ENTA
FCM
KAM
DTC
Jacobs Levy Equity Management's ENTA Position: Q4 2025 in Review
Jacobs Levy Equity Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 169,048 shares — an estimated $2.02M sold.
Jacobs Levy Equity Management first reported a position in ENTA in Q1 2016 and held it in 31 quarters. The position peaked at $20.2M in Q4 2021. 131 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.
- Jacobs Levy Equity Management reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Jacobs Levy Equity Management sold 169,048 Enanta Pharmaceuticals shares in Q4 2025, an estimated $2.02M.
- Jacobs Levy Equity Management first reported a position in Enanta Pharmaceuticals in Q1 2016 and held it in 31 quarters.
- Jacobs Levy Equity Management's Enanta Pharmaceuticals position peaked at $20.2M in Q4 2021.
- 131 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.
Based on Jacobs Levy Equity Management's 13F filing for Q4 2025, filed 13 Feb 2026.